iShares Biotechnology ETF
Price through Oct 2 · Flows through Oct 2. Figures use the latest available records, not a live quote. Fund details retrieved Oct 3. Holdings snapshot retrieved Oct 3.
The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1M SHOWN · NET +$272M OVER THIS RANGE
Money keeps arriving — +$272M of net inflows over the past month, about 2.5% of the fund's asset base, while the price has returned +21.6% so far this year. At 0.45% a year it is not the cheapest way in — FDHT has a reported fee of 0.39%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | GILDGILEAD SCIENCES | 8.18% | $144.74 | -1.9% | ||
| 2 | AMGNAMGEN | 7.68% | $403.04 | -1.0% | ||
| 3 | VRTXVERTEX PHARMACEUTICALS | 7.55% | $504.73 | -0.4% | ||
| 4 | REGNREGENERON PHARMACEUTICALS | 5.23% | $735.20 | +0.1% | ||
| 5 | MRNAMODERNA | 4.95% | $190.01 | +0.6% | ||
| 6 | NTRANATERA | 3.95% | $410.35 | +0.5% | ||
| 7 | ARGXARGENX SE | 3.73% | $919.21 | -1.8% | ||
| 8 | ILMNILLUMINA | 2.87% | $273.04 | +2.8% | ||
| 9 | RVMDREVOLUTION MEDICINES | 2.85% | $206.64 | +0.4% | ||
| 10 | BIIBBIOGEN | 2.34% | $219.88 | -1.3% | ||
| 11 | ONCBeiGene | 2.17% | $358.07 | -0.2% | ||
| 12 | ALNYALNYLAM PHARMACEUTICALS | 2.21% | $219.72 | -5.0% | ||
| 13 | INSMINSMED | 1.68% | $111.12 | +2.3% | ||
| 14 | INCYINCYTE | 1.69% | $115.30 | -1.6% | ||
| 15 | UTHRUNITED THERAPEUTICS | 1.70% | $541.70 | -5.2% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 221| 1 week | -2.1% |
| 1 month | -4.0% |
| 3 months | +4.9% |
| 6 months | +20.7% |
| YTD | +21.6% |
| 1 year | +36.0% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | +$145M |
| 1 month | +$272M |
| 3 months | +$623M |
| YTD | +$492M |
| 1 year | +$1.8B |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 8.2% of the book; the top ten carry 49%. Spread across 229+ names, it behaves like roughly 31 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $24M | $31M |
| TEM TEMPUS AI INC | $6M | $6M |
| IOVA IOVANCE BIOTHERAPEUTICS | $4M | $4M |
| IBRX IMMUNITYBIO | $4M | $3M |
| VRTX VERTEX PHARMACEUTICALS | $2M | $3M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat IBB on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| IVV iShares Core S&P 500 ETF | 0.03% | $881.6B | +$14.6B | -42bp on fee · 81× the assets · +$14.6B in over the month | Head-to-head |
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.5B | +$286M | -42bp on fee · 4× the assets · +$286M in over the month | Head-to-head |
| BBUS JPMorgan BetaBuilders U.S. Equity ETF | 0.02% | $9.4B | +$187M | -43bp on fee · +$187M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.2B | +$199M | -42bp on fee · 2× the assets · +$199M in over the month | Head-to-head |
| SPYG State Street SPDR Portfolio S&P 500 Growth ETF | 0.04% | $56.2B | +$717M | -41bp on fee · 5× the assets · +$717M in over the month | Head-to-head |